Oniki K, Hori M, Takata K, Yokoyama T, Mihara S, Marubayashi T, et al
You can adjust this
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
W przypadku jakichkolwiek wtpliwoci dotyczcych dawkowania, zawsze warto zasign porady specjalisty , ktry pomoe dostosowa dawk do indywidualnych potrzeb pacjenta
ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity
